Expanded footprint Cytotheryx is rapidly expanding its real estate and manufacturing footprint with newly acquired facilities in Rochester, New York and Rochester, United Kingdom, signaling capacity growth and potential for scaled GMP production partnerships with pharma and biotech companies.

Strategic financing A $60M Series A alongside additional debt financing from Q Investments enables scale-up of manufacturing capabilities, real estate expansion, and operational scale, creating opportunities to engage for collaborative development programs and facility-access deals.

Product diversification Beyond primary human hepatocytes, Cytotheryx launched Cytocine Primary Porcine Hepatocytes, indicating interest in complementary cell sources and cross-species models that could broaden collaboration potential with CROs and academic labs exploring alternative liver models.

Validated demand New client win with Ouroboros (Obgfund) highlights market traction for its proprietary bio-incubator platform and scalable hepatocyte production, opening avenues to pursue additional pharmaceutical and biotech customers needing reliable cell sources.

Sustainability & scale Growing demand for high-quality PHH and the targeted expansion of GMP manufacturing capacity align Cytotheryx with pharma’s need for consistent, compliant liver cells, presenting opportunities for strategic partnerships, long-term supply agreements, and co-development initiatives.